Clinical trials: Perioperative Immunotherapy
Lung Neoplasm Malignant
Adebrelimab Plus Famitinib as Adjuvant Therapy in Non-pCR NSCLC
Neoadjuvant immunotherapy combined with chemotherapy followed by surgery has become an important treatment strategy for resectable non-small cell lung cancer (NSCLC).
- Trial name
- NCT07890636
- Testing
- Adebrelimab, Adjuvant treatment
- Where
- China
- Volunteers
- 64 people
- Sponsor
- Ruijin Hospital
Non-small Cell Lung Cancer, Minimal Residual Disease
Sintilimab Combined With Anlotinib for Perioperative Non-small Cell Lung Cancer Based on MRD Evaluation
To study the efficacy of sintilimab combined with anlotinib for perioperative non-small cell lung cancer. To explore the clearance effect of sintilimab combined with anlotinib for postoperative adjuvant therapy based on…
- Conditions
- Non-small Cell Lung Cancer, Minimal Residual Disease, Immunotherapy, Anti-angiogenesis
- Trial name
- NCT05460195
- Testing
- sintilimab combined with anlotinib, sintilimab monotherapy
- Where
- China
- Volunteers
- 42 people
- Sponsor
- Shanghai Chest Hospital
Non-small Cell Lung Cancer
NeoTRACK - Dissection of IO Efficacy in NSCLC by Longitudinal tracKing
Prospective, non-randomized, open-label, single-arm phase II trial to investigate the feasibility and efficacy of combining chemotherapy with tiragolumab and atezolizumab as neoadjuvant and adjuvant treatment for surgical NSCLC…
- Trial name
- NCT05825625
- Testing
- Atezolizumab, Tiragolumab
- Where
- 2 sites in Germany
- Volunteers
- 35 people
- Sponsor
- Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
HCC
A Multicenter, Prospective Study of Perioperative Finotonlimab Combined With Bevacizumab in Resectable Hepatocellular Carcinoma Patients With High-Risk Factors for Recurrence
For patients with early- to mid-stage hepatocellular carcinoma (HCC), the five-year postoperative recurrence and metastasis rate remains as high as 70%, significantly impacting patient prognosis.Therefore, perioperative therapy…
- Trial name
- NCT07009470
- Testing
- Finotonlimab (an anti-PD-1 monoclonal antibody) and Anbeizhu (a bevacizumab biosimilar), TACE
- Where
- China
- Volunteers
- 130 people
- Sponsor
- Tongji Hospital
HER2-positive, Locally Advanced Solid Tumor
SOX Combined With Sintilimab and Trastuzumab Versus SOX Regimen in the Perioperative Treatment of HER2-positive Locally Advanced Gastric Adenocarcinoma
The SOX regimen has became the standard perioperative chemotherapy for locally advanced gastric cancer; The immune checkpoint inhibitors have become a standard treatment for advanced or metastatic gastric cancer；For HER2-positive…
- Conditions
- HER2-positive, Locally Advanced Solid Tumor, Immunotherapy, Sintilimab
- Trial name
- NCT05218148
- Testing
- sintilimab, Trastuzumab, S-1 plus oxaliplatin
- Where
- China
- Volunteers
- 44 people
- Sponsor
- Aiping Zhou
Adenocarcinoma Stomach, Adenocarcinoma Gastroesophageal Junction
Zimberelimab + Domvanalimab in Gastroesophageal Adenocarcinoma
The purpose of the study is to understand whether study drugs domvanalimab and zimberelimab are safe and effective in combination with standard chemotherapy for patients with operable cancer of the esophagus, stomach, or…
- Trial name
- NCT07283848
- Testing
- Zimberelimab, Domvanalimab, FLOT (Fluorouracil+Leucovorin+Oxaliplatin+Docetaxel)
- Where
- United States
- Sponsor
- Massachusetts General Hospital
Renal Cell Carcinoma (RCC)
Perioperative TORIPALIMAB Plus LENVATINIB in Patients With Renal Cell Carcinoma Undergoing Nephrectomy (PLUTO)
The PLUTO-trial is a single-center, open-label, phase II trial investigating Toripalimab plus Lenvatinib in patients with multi-stage clear-cell renal cell carcinoma.
- Trial name
- PLUTO (NCT06114940)
- Testing
- Toripalimab, Lenvatinib
- Where
- China
- Volunteers
- 17 people
- Sponsor
- Jinling Hospital, China
Muscle Invasive Bladder Cancer
Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin
A global phase 3, multicenter, randomized, trial, to Determine the Efficacy and Safety of Durvalumab in combination with Tremelimumab and Enfortumab Vedotin or Durvalumab in combination with Enfortumab Vedotin for Perioperative…
- Trial name
- VOLGA (NCT04960709)
- Testing
- Durvalumab, Tremelimumab, Enfortumab Vedotin
- Where
- 196 sites in United States, Argentina and 23 more
- Volunteers
- 712 people
- Sponsor
- AstraZeneca
Clinical Stage II Esophageal Adenocarcinoma AJCC v8, Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8
Phase I/II Study of Perioperative Chemotherapy Plus Immunotherapy Followed by Surgery in Localized Esophageal and Gastroesophageal Adenocarcinoma
To learn if atezolizumab in combination with oxaliplatin and 5-fluorouracil (5-FU), when given before surgery, can help to control esophageal and/or gastroesophageal cancer.
- Conditions
- Clinical Stage II Esophageal Adenocarcinoma AJCC v8, Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IIA Esophageal Adenocarcinoma AJCC v8, Clinical Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8
- Trial name
- NCT03784326
- Testing
- Atezolizumab, Conventional Surgery, Fluorouracil
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- M.D. Anderson Cancer Center
Neoadjuvant Chemoimmunotherapy, Robotic Pulmonary Resection
Downstaging and RATS After Neo-Chemo-IO: Impact on Surgical Outcomes in NSCLC
The goal of this observational study is to learn whether tumor and nodal downstaging after neoadjuvant chemo-immunotherapy is associated with better surgical outcomes in patients with clinical stage IIB-III non-small cell lung…
- Conditions
- Neoadjuvant Chemoimmunotherapy, Robotic Pulmonary Resection, Stage IIB-III NSCLC
- Trial name
- DRAGON-NSCLC (NCT07528066)
- Testing
- Robotic-assisted surgery (RATS)
- Where
- 10 sites in China, France and 1 more
- Volunteers
- 200 people
- Sponsor
- Shanghai Chest Hospital
Nasopharyngeal Cancer Recurrent, Nasopharyngeal Cancinoma (NPC)
Perioperative Chemotherapy and Immunotherapy for Locally Recurrent Nasopharyngeal Carcinoma
Nasopharyngeal carcinoma (NPC) is an endemic malignancy in Southern China and southeast Asia. Despite intensive radical therapy, between 15% and 30% of NPC patients develop relapse.
- Trial name
- NCT07129772
- Testing
- Gemcitabine (GEM), Cisplatin, PEMBROLIZUMAB (alone or when added to a regimen above)
- Where
- Hong Kong
- Volunteers
- 53 people
- Sponsor
- The University of Hong Kong
Gastric (Cardia, Body) Cancer, Stomach Adenocarcinoma
Neoadjuvant Nab-Paclitaxel Plus Oxaliplatin, S-1, and Sintilimab in Early-Onset Resectable Gastric Cancer
This study aims to evaluate the effectiveness and safety of a preoperative treatment (called neoadjuvant therapy) combining four drugs-nab-paclitaxel, oxaliplatin, S-1, and sintilimab-for patients with locally advanced…
- Conditions
- Gastric (Cardia, Body) Cancer, Stomach Adenocarcinoma, Locally Advanced
- Trial name
- YOUNG-NEOS (NCT07018063)
- Testing
- nab-paclitaxel, oxaliplatin, S-1
- Where
- China
- Volunteers
- 35 people
- Sponsor
- zhoujing
Gastric Adenocarcinoma, Oesophageal Adenocarcinoma
Study Title: Peri-operative Immuno-Chemotherapy in Operable Oesophageal and Gastric Cancer
A single centre phase II trial of peri-operative chemo-immunotherapy in operable gastro-oesophageal adenocarcinoma (GOA). This trial is designed to evaluate the safety and efficacy of administering Avelumab, an anti-PD-L1…
- Trial name
- ICONIC (NCT03399071)
- Testing
- FLOT-A
- Where
- United Kingdom
- Volunteers
- 44 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Immunotherapy, Analgesia
Effect of Neoadjuvant Anti-PD-1 Immunotherapy on Perioperative Analgesia and Postoperative Delirium
To observe the effect of preoperative anti-PD-1 monotherapy combined with chemotherapy on patients' perioperative pain and opioid analgesia, and evaluate its effect on the incidence and severity of patients' postoperative…
- Conditions
- Immunotherapy, Analgesia, NSCLC, Delirium
- Trial name
- NCT05273827
- Testing
- neoadjuvant immunotherapy, Neoadjuvant chemotherapy
- Where
- 3 sites in China
- Volunteers
- 81 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Urinary Bladder Neoplasms, Immune Checkpoint Inhibitors
Perioperative Durvalumab With Neoadjuvant ddMVAC in Patients With Muscle-Invasive Bladder Cancer (NIAGARA-2)
The Phase II NIAGARA-2 study aims to expand on the data from the Phase III NIAGARA study by investigating perioperative durvalumab in combination with cisplatin based neoadjuvant chemotherapy in a clinical practice setting.
- Conditions
- Urinary Bladder Neoplasms, Immune Checkpoint Inhibitors, Methotrexate, Vinblastine
- Trial name
- NCT06960577
- Testing
- Durvalumab, Methotrexate, Vinblastine
- Where
- 59 sites in Australia, Brazil and 5 more
- Volunteers
- 150 people
- Sponsor
- AstraZeneca
Perioperative Immunotherapy, Limited Stage Lung Small Cell Carcinoma
Perioperative Immunotherapy for Resectable Limited-Stage SCLC
For limited-stage small cell lung cancer (SCLC), surgical treatment is recommended for patients with T1-2N0M0 (I-IIA) by guidelines.
- Conditions
- Perioperative Immunotherapy, Limited Stage Lung Small Cell Carcinoma, Resectable Small Cell Lung Cancer
- Trial name
- NCT07109401
- Testing
- Tislelizumab (BGB-A317) Plus Chemotherapy (Cisplatin/Carboplatin and Etoposide)
- Where
- China
- Volunteers
- 37 people
- Sponsor
- Fudan University
Clear Cell RCC
Perioperative Trial With IO/TKI for Multi-stage Clear Cell Renal Cell Carcinoma
The IO/TKI regimens which combines Immune checkpoint inhibitors (IO) with Tyrosine Kinase Inhibitors (TKI) have become the standard first-line option for advanced ccRCC.
- Trial name
- TRIPLE-PATH (NCT07571551)
- Testing
- Toripalimab, Lenvatinib
- Where
- China
- Volunteers
- 75 people
- Sponsor
- Jinling Hospital, China
Recurrent Triple-Negative Breast Cancer
Pembrolizumab + Paclitaxel +/- Bevacizumab for Triple-negative Breast Cancer
Breast cancer is histologically divided into non-invasive (approximately 10%) and invasive (approximately 90%), with invasive cancer being the target of chemotherapy.
- Trial name
- PRELUDE (NCT06976944)
- Testing
- Pembrolizumab, Paclitaxel, Bevacizumab
- Where
- 14 sites in Japan
- Volunteers
- 24 people
- Sponsor
- Yukinori Ozaki
Melanoma, Acral Melanoma
A Study of QL1706 Combined With OH2 Injection in Perioperative Treatment of Stage III Resectable Acral Melanoma
This is a prospective, multicenter, open-label, 1:1 randomized phase II trial enrolling 76 patients with AJCC stage III surgically resectable acral melanoma.
- Trial name
- NCT07854522
- Testing
- Iparomlimab and Tuvonralimab Injection (QL1706), OH2 Injection(Recombinant Human GM-CSF Oncolytic Type II Herpes Simplex Virus)
- Volunteers
- 76 people
- Sponsor
- Peking University Cancer Hospital & Institute
Non-Small Cell Lung Cancer
Demographics, Clinical Characteristics and Outcomes in Resected Non-Small Cell Lung Cancer Patients Receiving Immunotherapy in Europe and Canada
This study uses existing medical records to better understand how immunotherapy is used in people in Europe and Canada with non-small cell lung cancer (NSCLC) who undergo surgery.
- Trial name
- NCT07718139
- Testing
- nivolumab, pembrolizumab, durvalumab
- Where
- United Kingdom
- Volunteers
- 300 people
- Sponsor
- Bristol-Myers Squibb